Anavex Life Sciences Corp. (NASDAQ:AVXL) received a $15.00 price objective from investment analysts at Maxim Group in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would suggest a potential upside of 260.58% from the stock’s previous close.

AVXL has been the topic of a number of other research reports. Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, August 9th. Zacks Investment Research lowered Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Finally, ValuEngine raised Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd.

Shares of Anavex Life Sciences Corp. (AVXL) traded down 0.48% during midday trading on Monday, hitting $4.16. 266,935 shares of the stock were exchanged. The company’s market cap is $175.44 million. Anavex Life Sciences Corp. has a one year low of $2.76 and a one year high of $6.64. The firm has a 50 day moving average of $4.33 and a 200-day moving average of $4.33.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.09). Equities analysts expect that Anavex Life Sciences Corp. will post ($0.37) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target by Maxim Group Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/30/anavex-life-sciences-corp-avxl-given-a-15-00-price-target-by-maxim-group-analysts.html.

A number of hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its holdings in Anavex Life Sciences Corp. by 37.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 8,728 shares during the period. State Street Corp grew its holdings in Anavex Life Sciences Corp. by 15.2% in the second quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock valued at $3,210,000 after purchasing an additional 79,516 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in Anavex Life Sciences Corp. in the second quarter valued at $186,000. Vanguard Group Inc. grew its holdings in Anavex Life Sciences Corp. by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,617,757 shares of the biotechnology company’s stock valued at $8,606,000 after purchasing an additional 132,076 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Anavex Life Sciences Corp. by 16.0% in the second quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock valued at $2,282,000 after purchasing an additional 59,069 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.